Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
11/08/17Proteon Therapeutics to Present at the Stifel 2017 Healthcare Conference November 15thPrinter Friendly Version
11/07/17Proteon Therapeutics Announces Third Quarter 2017 Financial ResultsPrinter Friendly Version
09/05/17Proteon Therapeutics to Present at the Baird 2017 Global Healthcare Conference September 7, 2017Printer Friendly Version
08/07/17Proteon Therapeutics Announces Second Quarter 2017 Financial ResultsPrinter Friendly Version
08/02/17Proteon Therapeutics Announces Closing of $22 Million Convertible Preferred Stock FinancingPrinter Friendly Version
06/22/17Proteon Therapeutics Announces $22.0 Million Private PlacementPrinter Friendly Version
06/15/17Proteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 21stPrinter Friendly Version
05/10/17Proteon Therapeutics Announces First Quarter 2017 Financial ResultsPrinter Friendly Version
05/10/17Proteon Therapeutics Receives FDA Breakthrough Therapy Designation for VonapanitasePrinter Friendly Version
05/02/17Proteon Therapeutics Announces Increase to Enrollment of Ongoing Phase 3 PATENCY-2 Clinical TrialPrinter Friendly Version
05/01/17Proteon Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care Conference May 4thPrinter Friendly Version
03/17/17Proteon Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference March 22ndPrinter Friendly Version
03/16/17Proteon Therapeutics Announces Full-Year 2016 Financial Results and Changes to the Ongoing Phase 3 PATENCY-2 Clinical TrialPrinter Friendly Version
02/06/17Proteon Therapeutics Announces Two Presentations at the American Society of Diagnostic and Interventional Nephrology Meeting  Printer Friendly Version
12/13/16Proteon Therapeutics Announces Top-Line Data from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with CKDPrinter Friendly Version
11/10/16Proteon Therapeutics Announces First Patient Dosed in Phase 1 Study Evaluating Vonapanitase for the Treatment of Peripheral Artery Disease Below the KneePrinter Friendly Version
11/09/16Proteon Therapeutics to Participate in Two Upcoming Investor ConferencesPrinter Friendly Version
11/07/16Proteon Therapeutics Announces Third Quarter 2016 Financial ResultsPrinter Friendly Version
10/25/16Proteon Therapeutics Announces Overview of Phase 1 Clinical Program of Investigational Vonapanitase in Peripheral Artery Disease to be Presented at the 28th Transcatheter Cardiovascular Therapeutics (TCT) ConferencePrinter Friendly Version
10/20/16Proteon Therapeutics Appoints Paul Hastings Chairman of Its Board of DirectorsPrinter Friendly Version
09/01/16Proteon Therapeutics to Present at Two Upcoming Investor ConferencesPrinter Friendly Version
08/08/16Proteon Therapeutics Announces Second Quarter 2016 Financial ResultsPrinter Friendly Version
06/15/16Proteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 22ndPrinter Friendly Version
05/09/16Proteon Therapeutics Announces First Quarter 2016 Financial ResultsPrinter Friendly Version
04/28/16Proteon Therapeutics Announces Survey Findings Demonstrating Impact of Vascular Access Failure on Hemodialysis PatientsPrinter Friendly Version
04/13/16Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery DiseasePrinter Friendly Version
03/14/16Proteon Therapeutics Announces Fourth Quarter and Full-Year 2015 Financial ResultsPrinter Friendly Version
03/02/16Proteon Therapeutics to Present at the Cowen and Company 36th Annual Health Care Conference on March 8thPrinter Friendly Version
02/02/16Proteon Therapeutics to Present at the 2016 BIO CEO & Investor Conference February 8thPrinter Friendly Version
12/02/15Proteon Therapeutics to Present at the Oppenheimer 26th Annual Healthcare Conference December 9thPrinter Friendly Version
11/13/15Proteon Therapeutics to Present at the Stifel 2015 Healthcare Conference on November 17thPrinter Friendly Version
11/12/15Proteon Therapeutics Announces Third Quarter 2015 Financial ResultsPrinter Friendly Version
11/09/15Proteon Therapeutics to Host Research and Development Day on November 20, 2015Printer Friendly Version
11/02/15Proteon Therapeutics Completes Enrollment in PATENCY-1, First Phase 3 Clinical Study of Investigational VonapanitasePrinter Friendly Version
10/28/15Proteon Therapeutics to Present at the BIO-Europe 2015 Conference November 3Printer Friendly Version
10/19/15Proteon Therapeutics Appoints Tony Kingsley to Its Board of DirectorsPrinter Friendly Version
10/12/15Proteon Therapeutics Announces Results from Phase 1 Study of Investigational Drug Vonapanitase in Patients with Symptomatic Peripheral Artery Disease Presented at TCT 2015Printer Friendly Version
09/02/15Proteon Therapeutics to Present at Two Upcoming Investor ConferencesPrinter Friendly Version
09/01/15Proteon Therapeutics Appoints Jennifer Panagoulias as Vice President of Regulatory AffairsPrinter Friendly Version
08/13/15Proteon Therapeutics Announces Second Quarter 2015 Financial ResultsPrinter Friendly Version
08/13/15Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery DiseasePrinter Friendly Version
08/12/15Proteon Therapeutics Initiates Second Phase 3 Clinical Study of Investigational Drug VonapanitasePrinter Friendly Version
07/22/15Proteon Therapeutics Appoints Scott Canute to Its Board of DirectorsPrinter Friendly Version
06/29/15Proteon Therapeutics Announces Addition to Russell 2000 IndexPrinter Friendly Version
06/17/15Proteon Therapeutics to Present at the JMP Securities Life Science Conference June 24thPrinter Friendly Version
06/02/15Proteon Therapeutics Appoints Scott Toner as Senior Vice President of MarketingPrinter Friendly Version
05/22/15Proteon Therapeutics to Present at Upcoming ERA-EDTA Annual CongressPrinter Friendly Version
05/13/15Proteon Therapeutics Announces First Quarter 2015 Financial ResultsPrinter Friendly Version
04/13/15Proteon Therapeutics to Present at Two International Vascular Access ConferencesPrinter Friendly Version
03/26/15Proteon Therapeutics Announces Positive Long-Term Results From Phase 2 Study of Investigational New Drug Vonapanitase in Chronic Kidney Disease Patients Undergoing Surgical Creation of an Arteriovenous Fistula for HemodialysisPrinter Friendly Version
03/20/15Proteon Therapeutics Announces Fourth Quarter and Full-Year 2014 Financial ResultsPrinter Friendly Version
02/26/15Proteon Therapeutics to Present at the Cowen and Company 35th Annual Healthcare Conference on March 4thPrinter Friendly Version
02/06/15Proteon Therapeutics to Ring the Nasdaq Stock Market Opening Bell on February 9thPrinter Friendly Version
02/05/15Proteon Therapeutics to Present at the 17th Annual BIO CEO & Investor Conference February 9thPrinter Friendly Version
01/08/15Journal of Cardiovascular Pharmacology Publishes Positive Nonclinical Results of Proteon Therapeutics' PRT-201 in Peripheral Artery DiseasePrinter Friendly Version
12/08/14Proteon Therapeutics to Present at the Oppenheimer 25th Annual Healthcare Conference December 11thPrinter Friendly Version
11/25/14Proteon Therapeutics Announces Third Quarter 2014 Financial ResultsPrinter Friendly Version
11/24/14Proteon Therapeutics Announces the Closing of Initial Public Offering and the Underwriters' Option to Purchase Additional SharesPrinter Friendly Version
11/17/14Proteon Therapeutics to Present at the Stifel Nicolaus 2014 Healthcare Conference November 18thPrinter Friendly Version
10/21/14Proteon Therapeutics Announces Pricing of Initial Public OfferingPrinter Friendly Version
07/21/14Proteon Therapeutics Initiates Phase 3 Clinical Study of PRT-201 in Patients with Chronic Kidney Disease Undergoing Surgical Placement of an Arteriovenous Fistula for HemodialysisPrinter Friendly Version
05/16/14Proteon Therapeutics Announces $45 Million of Series D FinancingPrinter Friendly Version
05/14/14Proteon Therapeutics Announces Publication of Results from Phase 2 Study of PRT-201Printer Friendly Version
01/08/14Proteon Therapeutics Announces Orphan Drug Designation in the European Union for PRT-201Printer Friendly Version
02/04/13Proteon Therapeutics to Present at the 15th Annual BIO CEO & Investor ConferencePrinter Friendly Version
01/03/13Proteon Therapeutics Announces Positive Phase 2 Trial Results of PRT-201 in Chronic Kidney Disease Patients Undergoing Surgical Placement of an Arteriovenous Fistula for HemodialysisPrinter Friendly Version
10/15/12Proteon Therapeutics Initiates Patient Enrollment in Phase 1 Clinical Study of PRT-201 in Patients Suffering from Peripheral Artery DiseasePrinter Friendly Version
04/14/11Proteon Therapeutics Initiates Patient Enrollment in Phase 2 Clinical Study of PRT-201 in Hemodialysis PatientsPrinter Friendly Version
12/03/09Proteon Therapeutics Named 2010 Technology Pioneer by the World Economic ForumPrinter Friendly Version
11/23/09Proteon Initiates Second Phase 1/2 Clinical Study of PRT-201 in Hemodialysis PatientsPrinter Friendly Version
06/08/09Proteon Founders Nicholas Franano, M.D. and William P. Whitaker, Esq. Named Ernst & Young Entrepreneur Of The Year® 2009 Award Winners in the Central Midwest RegionPrinter Friendly Version
05/28/09Proteon Therapeutics Completes Second Closing of Equity Financing; Raises Total Series B to $50 millionPrinter Friendly Version
03/05/09Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement with Major Pharmaceutical CompanyPrinter Friendly Version